

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

666 Fifth Avenue
New York, New York 10103-3198
FAX: (212) 318-3400**FACSIMILE COVER SHEET**

PLEASE TRANSMIT THE FOLLOWING PAGES TO:

NAME: Examiner M. DibrinoCOMPANY/FIRM
(LOCATION): U.S. Patent and Trademark OfficeFACSIMILE 703-305-7401VOICE PHONE: 703-308-0061

From: <u>Norman D. Hanson</u>	Phone No.: <u>212-318-3168</u>	Number of Pages Sent: (Including Cover Sheet) <u>6</u>
Date: <u>August 6, 2001</u>	User No.: <u>01030</u>	Flr: <u>24</u> Matter No.: <u>09807811</u>
Return Transmitted Fax To: <u>Annette Crossan</u>		Internet: <u>nhanson@fulbright.com</u>

Re:

REMARKS:

If you experience problems with this transmission or have questions, please call 212-318-3250.

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by telephone and return the original message to Fulbright & Jaworski L.L.P. at the above address via the U.S. Postal Service at our expense. Thank you.

*** RX REPORT ***

RECEPTION OK

TX/RX NO	5225	
CONNECTION TEL		212 318 3111
SUBADDRESS		
CONNECTION ID		
ST. TIME	08/06 11:16	
USAGE T	01'42	
PGS.	6	
RESULT	OK	

VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted
to US Patent and Trademark Office on August 6, 2001.

[Signature]
Signature

LUD-5466.4 - JEL/NDH (09807811)

20/2
ES/8/10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Knuth, et al.
Serial No. : 09/165,546
Filed : October 2, 1998
For : ISOLATED PEPTIDES CORRESPONDING TO
AMINO ACID SEQUENCES OF NY-ESO-1. . .
Group Art Unit : 1644
Examiner : M. Dibrino

OFFICIAL

August 6, 2001

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR § 1.111

S I R:

Responsive to the office action dated May 22, 2001, please amend this application as follows:

IN THE SPECIFICATION

Page 6, lines 4-5: replace by:

Figure 3 shows potential sites for modification of the deduced amino acid sequence of NY-ESO-1 (the amino acid sequence is encoded by the nucleotide sequence of SEQ ID NO: 1, and is set forth therein).